Pharmacy

High drug prices continue to plague payers, but various contributing factors intensify the problem.

Find out what’s in the drug pipeline for autoimmune disease.

The 21st Century Cures Act, a landmark medical research bill, offers healthcare executives a promising future.

Pharmaceutical manufacturer relationships and next-gen value based contracts are primed to accelerate value-derivation from your drug spend.

Experts share their ideas on how President-elect Trump could change the single largest source of insurance in the country.

Results from Managed Healthcare Executive’s annual State of the Industry Survey reveal which issues will hit managed healthcare hardest in 2017.

As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.

There now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study

Plans and PBMs are finding new ways to rein in pharmacy costs.

Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.

Here’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.

The Independence Blue Cross Foundation Healthy Hearts Initiative aims to improve survival rates for sudden cardiac arrest, increase CPR preparedness.

The path to bundled payment success can be daunting. Here’s three universal concepts that will promote success under the various CMS models.

Rise in use of outpatient care and professional services contributed to quicker growth in spending for the privately insured over previous years.

Retail clinics emerge as a way to satisfy the growing demand for healthcare created by the newly insured under the ACA, but contrary to expectations, they do not appear to be leading to meaningful reductions in low-acuity ED visits.

Understand Medicare Part D’s design and its coverage gap to offer the most affordable prescription drug options for patients.

Here’s a three-pronged approach to improve adherence program efficiency that leverages predictive data analytics, hospital on-site pharmacies and post discharge follow-up evaluation to achieve real, measurable results.

Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.

Research by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.

Study examines the effectiveness of the Walgreens Connected Care CF program compared to a matched sample of control patients.

Failure to report accurate data can result in significant penalties for Medicaid managed care plans.

Alcohol and drug dependency treatment goals can tied to an insurer’s pay-for-performance incentive program. Here’s how.

Here’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.

As part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder.

Consumers are demanding transparency in the prices of drugs. Here’s how they are getting it.

Do copay assistance program offer a long-term solution for patients? Experts weigh in.

The advantages of using an advanced clinical decision support system fall into four general “reducing” categories. Here they are.

It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.

MCOs are going to have to step up their efforts to impact the growing opioid epidemic in this country.

Executives need to increase awareness in the category and ensure prescribers are aware of CDC guidelines for opioid prescribing and the prescription drug monitoring programs.